Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDOR-1134-2831
- Development stage
- Unknown
- Lead developer
- Idorsia
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
IDOR-1134-2831 is a synthetic glycan vaccine developed by Idorsia for the prevention of Clostridium difficile infection. The vaccine consists of small fragments of oligosaccharides designed to induce an immune response and includes a carrier protein, alpha-galactosylceramide. It acts as an immunostimulant and is part of Idorsia’s synthetic glycan vaccine platform. The drug is currently in Phase 1 clinical pharmacology studies to assess safety, tolerability, and immunogenicity in healthy participants[2][3][4][5][6].
02
Targets
iNKT TCR (Invariant natural killer T-cell receptor)PSII (Polysaccharide II antigen)
Beyond the preview
Go deeper on IDOR-1134-2831.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDOR-1134-2831.